霍奇金淋巴瘤复发:二线及后续治疗。

Q4 Medicine
Revue Du Praticien Pub Date : 2023-06-01
Bénédicte Deau Fischer
{"title":"霍奇金淋巴瘤复发:二线及后续治疗。","authors":"Bénédicte Deau Fischer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Relapse of hodgkin's lymphoma: </strong>2ND AND SUBSEQUENT LINE TREATMENTS. Patients who fail first-line treatment can be cured with salvage chemotherapy followed by intensified therapy and hematopoietic stem cell autotransplantation. This treatment strategy is feasible for patients who are eligible based on their age, with chemosensitive disease and associated comorbidities. There is no standard of care for salvage chemotherapy, but patients who are in complete remission prior to transplantation have the best prognosis. Combinations of salvage therapy, including new molecules, have shown interesting results, but without comparative trials. The use of brentuximab vedotin as a maintenance treatment post autotransplant has been evaluated for patients at high risk of relapse, resulting in a significant improvement in progression-free survival. Allograft is a curative option for postautotransplant relapse; however, immunotherapy with antiPD1 calls into question the role and timing of allograft.</p>","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 6","pages":"633-636"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Relapse of Hodgkin lymphoma: second and subsequent line treatments].\",\"authors\":\"Bénédicte Deau Fischer\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Relapse of hodgkin's lymphoma: </strong>2ND AND SUBSEQUENT LINE TREATMENTS. Patients who fail first-line treatment can be cured with salvage chemotherapy followed by intensified therapy and hematopoietic stem cell autotransplantation. This treatment strategy is feasible for patients who are eligible based on their age, with chemosensitive disease and associated comorbidities. There is no standard of care for salvage chemotherapy, but patients who are in complete remission prior to transplantation have the best prognosis. Combinations of salvage therapy, including new molecules, have shown interesting results, but without comparative trials. The use of brentuximab vedotin as a maintenance treatment post autotransplant has been evaluated for patients at high risk of relapse, resulting in a significant improvement in progression-free survival. Allograft is a curative option for postautotransplant relapse; however, immunotherapy with antiPD1 calls into question the role and timing of allograft.</p>\",\"PeriodicalId\":21248,\"journal\":{\"name\":\"Revue Du Praticien\",\"volume\":\"73 6\",\"pages\":\"633-636\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue Du Praticien\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Du Praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

霍奇金淋巴瘤复发:二线及后续治疗。一线治疗失败的患者可通过补救性化疗、强化治疗和自体造血干细胞移植治愈。这种治疗策略对于年龄符合条件、有化疗敏感性疾病和相关合并症的患者是可行的。挽救性化疗没有标准的护理,但移植前完全缓解的患者预后最好。包括新分子在内的救助疗法组合已经显示出有趣的结果,但没有进行比较试验。brentuximab vedotin作为自体移植术后复发高风险患者的维持治疗已被评估,导致无进展生存期的显着改善。同种异体移植是自体移植后复发的一种治疗选择;然而,使用抗pd1免疫疗法对同种异体移植物的作用和时机提出了质疑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Relapse of Hodgkin lymphoma: second and subsequent line treatments].

Relapse of hodgkin's lymphoma: 2ND AND SUBSEQUENT LINE TREATMENTS. Patients who fail first-line treatment can be cured with salvage chemotherapy followed by intensified therapy and hematopoietic stem cell autotransplantation. This treatment strategy is feasible for patients who are eligible based on their age, with chemosensitive disease and associated comorbidities. There is no standard of care for salvage chemotherapy, but patients who are in complete remission prior to transplantation have the best prognosis. Combinations of salvage therapy, including new molecules, have shown interesting results, but without comparative trials. The use of brentuximab vedotin as a maintenance treatment post autotransplant has been evaluated for patients at high risk of relapse, resulting in a significant improvement in progression-free survival. Allograft is a curative option for postautotransplant relapse; however, immunotherapy with antiPD1 calls into question the role and timing of allograft.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revue Du Praticien
Revue Du Praticien Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
161
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信